Vertex's Triple CF Combo Gets EU Approval Nod; Rejection For Daiichi Sankyo

EU approval is likely for the eight medicines that got the thumbs up this week from the European Medicines Agency's drug evaluation committee, the CHMP. The panel held fire on one product it had been considering and also issued its first rejection of 2020.

 hands holding jigsaw puzzles, business to business, business matching concept
Kaftrio is set to become Europe's first triple combination therapy for CF • Source: Shutterstock

The European Medicines Agency this week recommended pan-EU approval for eight medicines including Vertex Pharmaceuticals’ triple combination therapy for cystic fibrosis. Once approved, the elexacaftor/tezacaftor/ivacaftor combination will become Europe’s first such therapy for many CF patients. 

Branded Trikafta in the US, where it was approved in October 2019, the combination will be sold under the brand...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet